Literature DB >> 33140321

Reappraisal of the T Category for Solitary Intrahepatic Cholangiocarcinoma by Tumor Size in 611 Early-Stage (T1-2N0M0) Patients After Hepatectomy: a Surveillance, Epidemiology, and End Results (SEER) Analysis.

YiPing Chen1, ShanGeng Weng2.   

Abstract

BACKGROUND: The association between tumor size and survival in patients with intrahepatic cholangiocarcinoma (ICC) after hepatectomy is controversial, and the T category in the American Joint Committee on Cancer (AJCC) stage for ICC is a topic of debate.
METHODS: Data from 611 T1-2N0M0 ICC patients classified by the AJCC 8th edition who underwent hepatectomy were extracted from the Surveillance, Epidemiology, and End Results (SEER) database during 1988-2015. Cancer-specific survival was evaluated using Kaplan-Meier analysis. The optimal cutoff value of solitary tumor size was used an adjusted p value approach to discriminating patient survival.
RESULTS: In the AJCC 8th staging system, using a 5-cm cut-off value of tumor size for solitary ICC without vascular invasion (S/VI-) was not associated with survival in T1 category (p = 0.201), and multifocal ICC with vascular invasion had a worse survival than solitary ICC with vascular invasion (S/VI+) in T2 category (p = 0.014). Tumor size was a prognostic factor for both S/VI- and S/VI+, the optimal cutoff value of tumor size was obtained 8 cm for S/VI- and 3 cm for S/VI+. S/VI- ≤ 8 cm had a similar survival to S/VI+ ≤ 3 cm (p = 0.126), S/VI- > 8 cm had a similar survival to S/VI+ > 3 cm (p = 0.655), and multifocal ICC had a similar survival with S/VI- > 8 cm (p = 0.159) and S/VI+ > 3 cm (p = 0.196). When the cohort was divided into two groups-new T1 (S/VI- ≤ 8 cm and S/VI+ ≤ 3 cm) and new T2 (S/VI- > 8 cm, S/VI+ > 3 cm and multifocal ICC)-significant survival difference was observed (p < 0.0001).
CONCLUSIONS: The discriminatory power of the AJCC 8th edition for solitary ICC could be further enhanced by subdividing tumors according to size and vascular invasion (8 cm for S/VI- and 3 cm for S/VI+).
© 2020. The Society for Surgery of the Alimentary Tract.

Entities:  

Keywords:  Intrahepatic cholangiocarcinoma; SEER; T category; Tumor size

Mesh:

Year:  2020        PMID: 33140321     DOI: 10.1007/s11605-020-04833-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  24 in total

1.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

2.  Tumor size predicts vascular invasion and histologic grade among patients undergoing resection of intrahepatic cholangiocarcinoma.

Authors:  Gaya Spolverato; Aslam Ejaz; Yuhree Kim; Georgios C Sotiropoulos; Andreas Pau; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Todd W Bauer; Dustin M Walters; Ryan Groeschl; T Clark Gamblin; Wallis Marsh; Kevin T Nguyen; Ryan Turley; Irinel Popescu; Catherine Hubert; Stephanie Meyer; Jean-Francois Gigot; Gilles Mentha; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2014-05-20       Impact factor: 3.452

3.  Intra-hepatic cholangiocarcinoma--frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center.

Authors:  Ashwani K Singal; Jean-Nicolas Vauthey; James J Grady; John R Stroehlein
Journal:  J Cancer Res Clin Oncol       Date:  2011-01-05       Impact factor: 4.553

4.  Outcomes of resection for solitary ≤5 cm intrahepatic cholangiocarcinoma.

Authors:  Paola Tarchi; Parissa Tabrizian; Jake Prigoff; Myron Schwartz
Journal:  Surgery       Date:  2017-12-23       Impact factor: 3.982

Review 5.  Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis.

Authors:  Michael N Mavros; Konstantinos P Economopoulos; Vangelis G Alexiou; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2014-06       Impact factor: 14.766

6.  Is Hepatic Resection for Large or Multifocal Intrahepatic Cholangiocarcinoma Justified? Results from a Multi-Institutional Collaboration.

Authors:  Gaya Spolverato; Yuhree Kim; Sorin Alexandrescu; Irinel Popescu; Hugo P Marques; Luca Aldrighetti; T Clark Gamblin; John Miura; Shishir K Maithel; Malcolm H Squires; Carlo Pulitano; Charbel Sandroussi; Gilles Mentha; Todd W Bauer; Timothy Newhook; Feng Shen; George A Poultsides; J Wallis Marsh; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2014-10-30       Impact factor: 5.344

7.  A proposed staging system for intrahepatic cholangiocarcinoma.

Authors:  Hari Nathan; Thomas A Aloia; Jean-Nicolas Vauthey; Eddie K Abdalla; Andrew X Zhu; Richard D Schulick; Michael A Choti; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2008-11-06       Impact factor: 5.344

Review 8.  Multimodality treatment of intrahepatic cholangiocarcinoma: A review.

Authors:  Kerri A Simo; Laura E Halpin; Nicole M McBrier; Jacob A Hessey; Erin Baker; Samuel Ross; Ryan Z Swan; David A Iannitti; John B Martinie
Journal:  J Surg Oncol       Date:  2016-01       Impact factor: 3.454

9.  A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience.

Authors:  Omar Hyder; Hugo Marques; Carlo Pulitano; J Wallis Marsh; Sorin Alexandrescu; Todd W Bauer; T Clark Gamblin; Georgios C Sotiropoulos; Andreas Paul; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Cristina R Ferrone; Andrew X Zhu; Irinel Popescu; Jean-Francois Gigot; Gilles Mentha; Shen Feng; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2014-05       Impact factor: 14.766

10.  Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan.

Authors:  Yoshihiro Sakamoto; Norihiro Kokudo; Yutaka Matsuyama; Michiie Sakamoto; Namiki Izumi; Masumi Kadoya; Shuichi Kaneko; Yonson Ku; Masatoshi Kudo; Tadatoshi Takayama; Osamu Nakashima
Journal:  Cancer       Date:  2015-10-02       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.